| Literature DB >> 35471166 |
Viviana Alexandra Martínez-Villota1, Paulo Francisco Mera-Martínez2, José Darío Portillo-Miño3.
Abstract
Bothrops spp. envenomation and its relationship with ischemic stroke has complex pathogenesis. Local effects such as edema, pain, redness, necrosis, and systemic manifestations like coagulation disorders, thrombosis, renal failure, and hemorrhage have been reported. Hemorrhagic stroke is a common neurological complication but ischemic stroke is poorly understood. We present here the case of a 50-year-old male with no comorbidities referred from a rural area in southwest Colombia with a Bothrops spp. snakebite on the left hand. On admission, the patient presented with a deterioration of consciousness and required mechanical ventilation assistance. The MRI showed multiple ischemic areas in the bilateral frontaltemporal and occipital regions. Two months later, the patient had a favorable resolution, although central paresis in the III and VI cranial nerves and positive Babinski's sign persisted. As already mentioned, the pathophysiology of ischemic stroke due to snakebite is complex but the procoagulant activity of the venom components, the hypovolemic shock, the endothelial damage, and the thromboinflammation can explain it, and although it rarely occurs, it should be considered as a complication of ophidian accidents caused by Bothrops spp.Entities:
Keywords: stroke; bothrops; snake bites; snake venoms
Mesh:
Year: 2022 PMID: 35471166 PMCID: PMC9045098 DOI: 10.7705/biomedica.6114
Source DB: PubMed Journal: Biomedica ISSN: 0120-4157 Impact factor: 1.173
Description of the reported cases of ischemic stroke and Bothrops snakebite
| No. case | Year and reference | Country | Snakebite | Vascular territory | Laboratory tests on admission | Deficit |
|---|---|---|---|---|---|---|
| 1 | Numeric, | Martinica | Right ACA and multiple small foci in cerebellar cortex, right PCA, both MCA | CK: 1212 U/L (26-174); CRP: 147.7 mg/L (0-10); PTT: 29 s (control: 32); fibrinogen 6.33 g/L (2-4); D dimer: positive; PLT 201000 | Left hemiplegia and a partial Wernicke’s aphasia | |
| 2 | Angarita, | Colombia | Right MCA, left MCA | PT> 2 min; PTT>2 min PLT : 23.500 | Ocular deviation to the right, dysarthria, left hemiparesis, bilateral Babinski | |
| 3 | Merle, | Martinica | Right PCA | PLT: 52,000 cells/mm3 PT: 14% (70-100%), aPTT: 51 s (normal, 32); fibrinogen <0.5 g/L (2-4 g/L); factor II level 66% (70- 120%); factor V level 17% (70-120%); FDP: 2560 pg/ml (normal <5 g/ml) | Left, lateral, homonymous quadranopsia with macular epargne | |
| 4 | Thomas, | Martinica | Both PCA | PLT: 57,000; fibrinogen<0,5 (g/l); PT: 34 s; aPTT: 51 sec; FDP: 2560 pg/ml; CRP 1,9 mg/ml | Right hemiparesis and aphasia | |
| 5 | Thomas, | Martinica | Left MCA | PLT: 20000; fibrinogen 2,45 (g/l); PT: 15 s; aPTT: 35 s; FDP: 320 pg/ml; CRP: 25,3 mg/ml | Right hemiparesis and aphasia | |
| 6 | Thomas, | Martinica | Both PCA, left MCA | PLT: 260,000; fibrinogen 2,81 (g/l); PT: 13 s; aPTT: 28 s; CRP: 0 mg/ml | Left hemiparesis and left homonymous hemianopsia. | |
| 7 | Cañas, | Colombia | Basilar artery | PLT: 18,000/mm3, PT>1 min A PTT>1 min; fibrinogen was not detected | Comatose, miotic pupils without reaction to light and generalized hypotonia, lack of response of limbs to painful stimuli, bilateral Babinski | |
| 8 | Martinez- Colombia Villota | Colombia | MCA | PT: 44 sec; blood test, normal; liver and renal function, normal; fibrinogen<50 mg/ml | Impaired level of consciousness, agitation, and left hemiparesis |
PT: Prothrombin time; PTT: Partial thromboplastin time; acPTT: Activated cephalin time or partial thromboplastin time; PLT: Platelet, CK: Creatine kinase; CRP: C-reactive protein; ACA: Anterior cerebral artery; MCA: Middle cerebral artery; PCA: Posterior cerebral arteries; FDP: Fibrin degradation product
Figure 1MRI (DWI) showing multiple areas of bilateral fronto-temporal, and occipital ischemia.
Figure 2Flow-diagram of probable pathophysiology mechanisms of ischemic stroke in the Bothrops envenomation.
Main procoagulant and anticoagulant molecules of the hemostatic system of the Bothrops snake
| Anticoagulants factors | Procoagulants factors | |
|---|---|---|
| A. Thromboinflammation | ||
| A. Aspercitin, hemorrhages, metalloproteinases: these substances can cause thrombocytopenia, prolongation PT and PTT, and disseminated intravascular coagulation. They produce hemorrhages of the cerebral parenchymal and subarachnoid | Immune system: activation of the function and migration of the leucocytes release of pro-inflammatory mediators (IL-1β, IL-6, IL-8, TNF-α, MIP-1α, NO, histamine, serotonin, PAF, bradykinin, PGE2, TXA2, LTB4, and RANTES) generation of anaphylatoxins (C3 and C5) generation of DAMPS, TF, and vW factor | Hemostatic system: - expression of procoagulant molecules (PT activators, thrombin agonist enzymes, factor X and V activators) - expression of pro-thrombotic and pro-fibrinolytic molecules (vW factor, TF, fibrinogen, C5 and C3) that interact with the platelet surface - activation of platelet receptors (PAR-1, PAR-4, GPIb-IX-V, GPVI, TLR2, and TLR4) activation of platelets by SV-CLRPs of a non-enzymatic pathway by interaction of toxins with the CLEC-2 receptor |
| B. Activation of c-protein through the activation of the serine proteases | B. Batroxobin: It is a serine protease similar to the thrombin of | |
| C. Inhibition of factor IX and X | C. Botrocetin: It is a heterodimeric protein snake venom isolated in | |
| D. Inhibition of the trombin through the bothrojaracine | D. Basparin a: It was isolated from the venom of | |
| E. Inhibition of the complexprothrombinase: action through the phospholipase A2 | E. Aspercitin, hemorrhages, and metalloproteinases: The cause of injury to the blood vessels wall produce cerebral infarct | |
| F. Fibrinolytic activity: adamalysin, fibrolase, atroxase, lebetase | F. Complement system: Activation of the 3 complement pathways, especially the lectin-C pathway through the hydrolysis of peptides C3, C4, and C5. The venom also acts directly on the C5a fragment for the generation of C5a convertase. The C1 inhibitor is a serine protease that regulates the complement cascade (inhibits C1r, C1s, and MASPs), and the coagulation cascade acting on fibrinolytic proteins (kallikrein, FXIIa, FXIa, and plasmin) | |
| G. Platelet aggregation inhibitors: α-fibrinogenase, phospholipase A2, 5'-nucleotidases, jarahagin, catrocollastatin, crovidisin, disintegrins, cerastatin, barbourin, albolabrin, cistrin, flavoviridine, elegantin, rhodostatin, tigramine | G. Platelet aggregation activators: Thrombocytin, cerastocytin, cerastobine, convuloxin, aggregoserpentin, trimucitin, agretin, bitiscentin, alboagregins, tocaracetin, flavocetins | |
PGE2: Prostaglandins; TXA2: Thromboxane; LTB4: Leukotrienes; C3 and C5: Complement fragments; DAMPs: Molecular patterns associated with damage; TF: Tissue factor; vW: von Willebrand factor; PAR-1, PAR-4: Protease activating receptors; GPIb-IX-V: GPIb-IX-V glycoprotein complex; GPIV: Glycoprotein VI;TLR2 and TLR4:Tolllike receptors; CLEC-2: C-type lectin receptor